Compositions and methods for promoting lipid mobilization in humans
AssigneeBLM Group
InventorsBernice Schacter, Lee P. Schacter
Life of this patent
Estimating the term…
Abstract
The invention provides methods of using polypeptide compounds based on the structures of insect peptides of the adipokinetic hormone family to mobilize lipids in humans. The compositions and methods described in the application are useful for modulating human body weight, such as inducing weight loss. The invention also includes screening methods for identifying other compounds effective for modulating lipid mobilization in humans.
Claims54
A method of promoting lipid mobilization in a human, the method comprising administering an insect adipokinetic hormone to the human in an amount effective to mobilize lipids in the human.
A method of promoting lipid mobilization in a human, the method comprising administering to the human, in an amount effective to mobilize lipids in the human, a compound having the chemical structure
- Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-X-Z,
- wherein:
- Xaa1 is a pyroglutamate residue;
- Xaa2 is one of a leucine residue, an isoleucine residue, a valine residue, a phenylalanine residue, and a tyrosine residue;
- Xaa3 is one of an asparagine residue and a threonine residue;
- Xaa4 is one of a phenylalanine residue and a tyrosine residue;
- Xaa5 is one of a threonine residue and a seine residue;
- Xaa6 is one of a proline residue, a serine residue, a threonine residue, and an alanine residue;
- Xaa7 is one of a glycine residue, an asparagine residue, a seine residue, an aspartate residue, a valine residue, and a tryptophan residue;
- Xaa8 is a tryptophan residue;
- X is from 0 to 10 amino acid residues;
- and
- Z is one of a hydrogen radical and a carboxyl terminus-blocking moiety.
A method of promoting lipid mobilization in a human, the method comprising administering to the human, in an amount effective to mobilize lipids in the human, a compound having the chemical structure
- Xaa1-Xaa22-Xaa23-Xaa24-Xaa25-Xaa26-Xaa27-Xaa28-X-Z,
- wherein:
- Xaa1 is a pyroglutamate residue;
- Xaa22 is an amino acid residue having a non-polar side chain;
- Xaa23 is an amino acid residue having a non-ionic polar side chain;
- Xaa24 is an amino acid residue having an aromatic side chain;
- Xaa25 is an amino acid residue having a non-ionic polar side chain;
- Xaa26 is any amino acid residue;
- Xaa27 is any amino acid residue;
- Xaa28 is an amino acid residue having an aromatic side chain;
- X is from 0 to 10 amino acid residues;
- and
- Z is one of a hydrogen radical and a carboxyl terminus-blocking moiety.
A method of promoting weight loss in a human, the method comprising administering an insect adipokinetic hormone to the human in an amount effective to mobilize lipids in the human.
A method of suppressing the appetite of a human, the method comprising administering an insect adipokinetic hormone to the human in an amount effective to mobilize lipids in the human, whereby the human's appetite is suppressed.
A method of promoting lipid mobilization in a human, the method comprising administering an insect adipokinetic hormone to the human in an amount effective to mobilize lipids in the human, wherein the hormone has the chemical structure
- Xaa1-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Z,
- wherein:
- Xaa1 is a pyroglutamate residue;
- Xaa3 is one of an asparagine residue and a threonine residue;
- Xaa4 is one of a phenylalanine residue and a tyrosine residue;
- Xaa5 is one of a threonine residue and a serine residue;
- Xaa6 is one of a proline residue, a serine residue, a threonine residue, and an alanine residue;
- Xaa7 is one of a glycine residue, an asparagine residue, a serine residue, an aspartate residue, a valine residue, and a tryptophan residue;
- Xaa8 is a tryptophan residue;
- and
- Z is one of a hydrogen radical and a carboxyl terminus-blocking moiety.
A method of promoting lipid mobilization in a human, the method comprising administering an insect adipokinetic hormone to the human in an amount effective to mobilize lipids in the human, wherein the hormone has the chemical structure
- Xaa1-Xaa3-Xaa4 -Xaa5-Xaa6-Lys-Z,
- wherein:
- Xaa1 is a pyroglutamate residue;
- Xaa3 is one of an asparagine residue and a threonine residue;
- Xaa4 is one of a phenylalanine residue and a tyrosine residue;
- Xaa5 is one of a threonine residue and a seine residue;
- Xaa6 is one of a proline residue, a serine residue, a threonine residue, and an alanine residue;
- and
- Z is one of a hydrogen radical and a carboxyl terminus-blocking moiety.
Dependencies are inferred from the claim text.